An antibody treatment has been shown to reduce mortality in patients hospitalized with severe COVID-19 by 20%, researchers at Regeneron Pharmaceuticals said Wednesday. The drug, REGEN-COV, was shown to be effective in seronegative patients, or patients who do not produce natural antibodies to the coronavirus, according to the results of Regeneron’s clinical trial released Wednesday. Seronegative patients…
The post Antibody Therapy Shown To Reduce Risk Of Death In COVID-19 Patients, Seeks FDA Approval appeared first on True Pundit.